Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Q3 2025 value amounting to $34.2 million.

  • Ironwood Pharmaceuticals' Change in Receivables rose 8896.38% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.2 million, marking a year-over-year increase of 19134.52%. This contributed to the annual value of -$47.2 million for FY2024, which is 501212.12% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Change in Receivables of $34.2 million as of Q3 2025, which was up 8896.38% from $46.4 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Change in Receivables high stood at $46.4 million for Q2 2025, and its period low was -$57.1 million during Q1 2024.
  • Its 5-year average for Change in Receivables is -$1.3 million, with a median of $3.2 million in 2023.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Change in Receivables soared by 440570.57% in 2022 and then tumbled by 52912.68% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Change in Receivables (Quarter) stood at $12.4 million in 2021, then tumbled by 107.55% to -$937000.0 in 2022, then surged by 588.47% to $4.6 million in 2023, then rose by 24.19% to $5.7 million in 2024, then surged by 501.57% to $34.2 million in 2025.
  • Its Change in Receivables stands at $34.2 million for Q3 2025, versus $46.4 million for Q2 2025 and -$42.1 million for Q1 2025.